The FDA has finalized new guidance offering recommendations on how drug firms can assure the safety of clinical trial participants, remain in compliance with good clinical practices and reduce trial integrity risks during the COVID-19 outbreak. The agency "recommends consultation with the appropriate review division regarding protocol modifications for the collection of efficacy endpoints, such as use of virtual assessments, delays in assessments, and alternative collection of research-specific specimens, if feasible."
FDA issues final guidance for trials amid coronavirus
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.